Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Samsung Biologics Raises $2 Billion in Korean IPO

publication date: Nov 11, 2016
Samsung Biologics completed a $2 billion IPO in South Korea at an $8 billion valuation. The company, a division of the large Samsung semiconductor conglomerate, has two divisions: a biologics contract manufacturer, and Bioepis, a joint venture with Biogen that makes biosimilar drugs. Samsung Biologics will use the proceeds to complete construction of its third manufacturing facility, a $740 million project, which will give it the biggest capacity of any biologic CMO and is expected to become operational in 2018. More details....

Stock Symbol: (KS: 207940) (NSDQ: BIIB)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital